Citations with the tag: BRISTOL-Myers Squibb Co
Results 1 - 50
- Bristol-Myers supports integrated healthcare as marketing approach.
// Medical Marketing & Media; Jan1998, Vol. 33 Issue 1, p8
Reports that the Second Annual Washington Conference on Integrated Patient Care in 1997 was supported by Bristol-Myers Squibb (BMS) as part of the company's major marketing program. BMS' company operations; Support of BMS for a study on maximizing healthcare value and quality.
- Bristol-Myers Squibb splits natl. contracts.
// FoodService Director; 01/15/98, Vol. 11 Issue 1, p6
Reports that a national contract for the foodservices in the Continental U.S. which was provided by Bristol-Myers Squibb, in Lawrenceville, New Jersey, has been divided between two companies. Identification of the companies; Inclusions in the agreement; Comments from Anthony W. Morro, manager,...
- New management.
// Crain's New York Business; 11/16/98, Vol. 14 Issue 46, p62
Focuses on changes in the management structure of Bristol-Myers Squibb Co.
- Bristol-Myers Squibb consolidates sales team.
// Drug Store News; 5/1/95, Vol. 17 Issue 6, p8
Reports on Bristol-Myers Squibb Co.'s move to consolidate the retail sales forces of its Bristol-Myers Products, Clairol and Mead Johnson Nutritionals divisions. Improvement of business operations.
- Bristol-Myers forms sales support organization.
// Drug Store News; 6/17/96, Vol. 18 Issue 9, p323
Reports on Bristol-Myers Squibb's establishment of the Bristol-Myers Consumer Sales Organization, designed to assist retailers by providing a single point of contact for the companies brands. Provision of the Total Business Solution.
- BMS sells Clairol division.
// Drug Topics; 11/22/93, Vol. 137 Issue 22, p79
Reports on Bristol-Myers Squibb Co.'s sale of its Clairol hair care appliance division to Remington Products Incorporated. Figure of annual sales; Products sold by the unit; Selling price per industry analysts.
- Consumers targeted by Capoten promo.
// Drug Topics; 9/5/94, Vol. 138 Issue 17, p8
Reports that Bristol-Myers Squibb has enlisted chain pharmacies in its first direct-to-consumer marketing campaign.
- A hard one to swallow.
// Drug Topics; 11/7/94, Vol. 138 Issue 21, p7
Reports that Bristol-Myers Squibb is withdrawing Questran tablets from the market after a patient choked on the large tablet.
- Managed care tool.
// Drug Topics; 3/4/96, Vol. 140 Issue 5, p34
Reports on Bristol-Myers Squibb's offering of a tool to measure patients' responses to treatment, to providers who treat patients with mental illness.
- New BMS group.
// Drug Topics; 7/22/96, Vol. 140 Issue 14, p21
Reports on Bristol-Myers Squibb's formation of a Consumer Sales Organization, unifying the sales groups within its three consumer products division.
- Labelers glide along smoothly for Bristol-Myers' ban.
Hartman, Lauren R. // Packaging Digest; Sep97, Vol. 34 Issue 10, p84
Focuses on the packaging of the Ban, clear soft solid antiperspirant/deodorant, by Bristol-Myers Squibb. Comments from Ken Laing, senior project engineering manager at Bristol-Myers; What discovery did Laing make; Description of the features of this product.
- Looting the medicine chest.
Nader, Ralph; Love, James // Progressive; Feb93, Vol. 57 Issue 2, p26
Discusses how the federal government helped Bristol-Myers Squibb gain a monopoly over the new cancer medicine Taxol and why it was unfair for the Bush administration to allow tax dollars and public lands to be used by a private company. Recent article in the `Journal of the National Cancer...
- Bristol-Myers shakeup.
Nader, Ralph; Love, James // Chemical Week; 1/5/94-1/12/94, Vol. 154 Issue 1, p8
Reports on the labor shakeup plans of drugs group Bristol-Myers Squibb. Reduction of 5,000 jobs; Restructuring of sales and marketing operations.
- Bristol's big gamble.
Wilkins, Richard D. // Business Journal Serving Southern Tier, CNY, Mohawk Valley, Fing; 4/3/95, Vol. 9 Issue 7, p1
Reports on the refusal by the company Bristol-Myers-Squibb to purchase a drug benefit manager. Expiration of the patent of Capoten; Buying medium sized companies that will strengthen core companies; Arrangement with Caremark International, Inc.; Sharing information on drug utilization from a...
Wilkins, Richard D. // Broadcasting & Cable; 4/26/93, Vol. 123 Issue 17, p81
Reports on Bristol-Myers Squibb's producing of a new half-hour prime time anthology series for Lifetime. Debut of `Amazing Love Stories' in October on the network; 13-episode series.
- Bristol mulls selling Clairol, Ban lines.
Sloan, Pat // Advertising Age; 3/8/93, Vol. 64 Issue 10, p2
Reports that Bristol-Myers Squibb Co. is considering selling its Clairol division as well as the Ban deodorant and Keri skincare lines. Leading marketers said to be interested in acquisition including Colgate-Palmolive Co.; Sale of the Clairol, Ban and Keri lines would effectively take the...
- BMS shops $20 mil. account.
Kim, Hank; Comiteau, Jennifer // Adweek New England Edition; 11/03/97, Vol. 34 Issue 44, p66
Reports that Bristol-Myers Squibb Co. has contacted at least one agency for its advertising account. Move as part of BMS' reassessment of the remainder of its business; BMS' reaction to Wells BDDP's resignation of the company's Clairol Herbal Essences shampoo account.
- BMS shops $20 Mil. account.
Kim, Hank; Comiteau, Jennifer // Adweek Western Edition; 11/03/97, Vol. 47 Issue 44, p67
States that Bristol-Myers Squibb company (BMS) has contacted at least one agency in relation to its $20 million Vagistat-1 account. Details on the account being at Wells BDDP; Why BMS contacted the agency.
- Bristol-Myers eyes consolidation.
Garcia, Shelly; Parpis, Eleftheria // Adweek Western Edition; 2/5/96, Vol. 46 Issue 6, p48
Reports that Bristol-Myers Squibb is moving toward the consolidation of its global advertising business. Advertising agencies working for the company; Reasons for the consolidations; Problems faced by companies in consolidating its advertising account.
- Bristol-Myers Squibb creates global divisions.
Garcia, Shelly; Parpis, Eleftheria // Brandweek; 5/9/94, Vol. 35 Issue 19, p6
Reports on Bristol-Myers Squibb's creation of three business units to promote the globalization of its brands. Worldwide Consumer Medicines; Worldwide Clairol; Blending of Asian consumer and nutritional businesses; Heads of each unit.
- Bristol cuts 5,000 jobs.
Harrington, John // Crain's New York Business; 1/10/94, Vol. 10 Issue 2, p22
Reports on Bristol-Myers Squibb's reduction of 5,000 jobs. Number of employees who accepted early retirement; Number of workers worldwide; Reason for the reduction.
- Bristol-Myers goes generic.
Harrington, John // Drug Topics; 1/22/96, Vol. 140 Issue 2, p7
Cites Bristol-Myers Squibb's creation of the division Apothecon Generic Development & Manufacturing Group. Division goals; Background information on the company.
- Taxy turvy world.
Harrington, John // Business News New Jersey; 06/30/97, Vol. 10 Issue 22, p3
Reports that Bristol-Myers Squibb received an $8.7 million income tax reimbursement over ten years from the state of New Jersey. Program that the grant comes from; Governor Christie Whitman's creation of the program; Where the facility is located.
- A drug firm hopes well.
Harrington, John // Business News New Jersey; 10/20/97, Vol. 10 Issue 36, p2
States that Bristol-Myers Squibb opened its facility in the week of October 13, 1997 in Hopewell, New Jersey. Description of the facility; Background information on Bristol-Myers; Functions of the facility; Statements made by chief executive officer Charles Heimbold.
- More liquid antibiotics withdrawn.
Harrington, John // FDA Consumer; Jul/Aug94, Vol. 28 Issue 6, p2
Informs that eight liquid oral antibiotics were voluntarily withdrawn from the market by Apothecon Division of Bristol-Myers Squibb Co. Finding of small plastic caps in the containers; Details.
- News update.
Harrington, John // Materials Management in Health Care; Sep96, Vol. 5 Issue 9, p10
Reports that Bristol-Myers Squibb plans to sell the infection and contamination control businesses of its ConvaTec division.
- After a few excedrin headaches local drug maker plans ambitious expansion.
Harting, Don // Business Journal Serving Southern Tier, CNY, Mohawk Valley, Fing; 4/1/96, Vol. 10 Issue 7, p1
Reports on Bristol-Myers Squibb Co.'s expansion plans for 1996. Plans to build a waste-water treatment plant; Plans to construct a new manufacturing plant; Company history; Nature of business; Number of employees as of April 1996; Revenues in 1995. INSET: What the pros are saying, by D.H..
- Bristol-Myers Squibb--a culture for EHS leadership.
Hellman, Thomas // Business Journal Serving Southern Tier, CNY, Mohawk Valley, Fing; 9/16/96, Vol. 10 Issue 19, p11B
Focuses on Bristol-Myers Squibb's commitment to responsible environmental, health, and safety management. Goals of the `EHS 2000' program; Product life-cycle improvements.
- Bristol rides high on marketing, R&D successes.
Hadley, Mark // Business Journal Serving Southern Tier, CNY, Mohawk Valley, Fing; 03/17/97, Vol. 11 Issue 6, p1
Presents news updates concerning Bristol-Myers Squibb Co.'s marketing and research and development processes. Processing and manufacturing of Taxol, a potent anticancer drug, with the National Cancer Institute; Chemical steps in producing the drug; Development of biological processes for...
- Broad sweep.
Horton, Kathleen // Pharmaceutical Executive; Jul97, Vol. 17 Issue 7, p90
Reports on Bristol-Myers Squibb's opening of a clinical research and development center in the Czech Republic for its Pharmaceutical Research Institute. Services to be rendered by the center; Bristol-Myers products undergoing clinical trials in the Czech Republic.
- New protease inhibitors being studied.
Horton, Kathleen // AIDS Patient Care & STDs; Oct97, Vol. 11 Issue 5, p374
Focuses on new research studies on two protease by Bristol-Myer Squibb Company. Details on the effectiveness of the of the two protease inhibitors; Information on the role played in triple-combination therapy; Amount of data released by Bristol-Myers Squibb.
- Ixsys joins forces with drug giant.
Horton, Kathleen // San Diego Business Journal; 7/5/93, Vol. 14 Issue 27, p14
Reports on Ixsys, Inc. collaborating with Bristol-Myers in developing monoclonal antibody drugs to treat tumors. Development of drugs to treat cancers of the lung, breast, colon and prostate; Terms of the agreement.
- Saxagliptin Tablets (Onglyza).
Elliott, William T.; Chan, James // Internal Medicine Alert; 9/29/2009, Vol. 31 Issue 18, p141
The article evaluates the diabetes mellitus treatment drug Saxaglipitin, Dipeptidyl peptidase-4 (DPP-4) by Bristol-Myers Squibb Co.
- Questran switch rejected.
Dickinson, James G. // Medical Marketing & Media; Nov97, Vol. 32 Issue 11, p32
Reports on the US Food and Drug Administration's (FDA) rejection of Bristol-Myers Squibb's application to switch prescription-only Questran and Questran Light to over-the-counter (OTC) status.
Dickinson, James G. // MondayMorning; 3/8/2010, Vol. 18 Issue 9, p12
No abstract available.
- Hospital, Bristol-Myers study hormone's effects.
Dickinson, James G. // AHA News; 3/6/95, Vol. 31 Issue 10, p5
Reports on the agreement by Bristol-Myers Squibb Co. and Massachusetts General Hospital to fund a research on melatonin. Function of melatonin in bodies of animals.
- Digging in.
Dickinson, James G. // Business News New Jersey; 11/1/95, Vol. 8 Issue 20, p54
Presents a photograph of Donna Jakubowski and Trish Champion of Bristol-Myers Squibb in helping two kids plant trees in New Jersey. New Leaf reforestation program.
- STOCK TO WATCH: BRISTOL-MYERS SQUIBB.
Sundaramoorthy, Geeta // Business News New Jersey; 03/14/2000, Vol. 13 Issue 11, p22
Examines the performance of the stock of diversified drug company, Bristol-Myers Squibb as of March 14, 2000. Change of the stock price due to competition; Speculations of analysts on the economic outlook of Bristol.
- Bristol-Myers Squibb breaks ground with direct response/product sampling website.
Kulpa, Jennifer // Drug Store News; 4/7/97, Vol. 19 Issue 7, p19
Reports that Bristol-Myers Squibb Co. and SiteSpecific Inc. have begun offering an online product sampling of Excedrin. Using the tactic to collect demographic data; Accessing the online service.
- Panel says yes.
Kulpa, Jennifer // Drug Topics; 8/2/93, Vol. 137 Issue 15, p52
Reports on the recommended approval of the Food and Drug Administration of Bristol Myers Squibb Co.'s nefazodone HCL, an agent for the treatment of depression. Serzone as brand name; Inhibiting presynaptic reuptake of serotonin and blocks postsynaptic 5HT2 receptors.
- Geriatric fellowship...
Kulpa, Jennifer // Drug Topics; 11/8/93, Vol. 137 Issue 21, p88
Announces the establishment of a postgraduate pharmaco-economics fellowship in geriatric long-term care at the American Society of Consultant Pharmacies (ASCP). Bristol-Myers Squibb as sponsor; Schedule; Application deadline; Contact address.
- FDA approves Taxol for breast cancer.
Kulpa, Jennifer // Drug Topics; 4/25/94, Vol. 138 Issue 8, p5
Reports on the approval by the Food and Drug Administration of the anticancer drug Taxol (paclitaxel). Bristol-Myers Squibb Co. as manufacturer; Role in treating advanced breast cancer.
- Bristol Myers Squibb Co. Charged By States With Unlawful Monopoly Of Widely Used Anti-Cancer Drug.
Kulpa, Jennifer // Insurance Advocate; 6/10/2002, Vol. 113 Issue 22, p38
Reports the antitrust lawsuit filed against Bristol Myers Squibb Co. in the U.S. on June 4, 2002 for allegedly planning to unlawfully hold exclusive possession over its anti-cancer drug Taxol.
- Quick and easy way to monitor forecasts.
Jain, Chaman L. // Journal of Business Forecasting Methods & Systems; Summer98, Vol. 17 Issue 2, p2
Editorial. Describes a method of monitoring forecasts through the cumulative sales ratio. Procedure followed at the Bristol-Myers Squibb Co.; Annual forecast of 1996 and their accuracy; Cumulative sales ratios of different companies.
- Movin' Out.
Jain, Chaman L. // njbiz; 2/10/2003, Vol. 16 Issue 6, p3
Reports on the plan of Bristol-Myers Squibb to close its distribution facility in Cranbury, New Jersey. Factors that contributed to the facility's shut down.
- Bristol-Myers Brings on Three Corporate Development Pros.
Cohen, Judy Radler // Mergers & Acquisitions Report; 5/13/2002, Vol. 15 Issue 19, p4
Announces the appointment of several executives in the pharmaceutical and healthcare company Bristol-Myers Squibb.
- Dasatinib Tablets (Sprycel).
Elliott, William T.; Chan, James // Internal Medicine Alert; 2/15/2007, Vol. 29 Issue 3, p21
The article discusses the indications, recommended dosage, potential advantages and disadvantages of Dasatinib, an orally active kinase inhibitor being marketed by Bristol-Myers Squibb as Sprycel.
- Bristol-Myers Q1 profit up 16.5 percent.
Reinhardt, Eric // Business Journal (Central New York); 5/7/2010, Vol. 24 Issue 19, p2
The article reports that pharmaceutical manufacturer Bristol-Myers Squibb Co.has gained an increase profit of 16.5 percent in the first quarter of 2010 in New York.
- Bristol-Myers Squibb Co. bows to pressure regarding ddI.
Delaney, Martin // Advocate; 5/7/91, Issue 576, p41
Reports on Bristol-Myers Squibb Co.'s filing of a new drug application for its antiviral drug Videx. Competitive pressure on the company.
- New and competitive.
Rodgers, Katie // Drug Topics; 2/6/95, Vol. 139 Issue 3, p32
Reports on the introduction of Bristol-Myers Squibb's (BMS) antidepressant Serzone (nefazodone). Price of Serzone as below the prevailing average wholesale price for selective serotonin reuptake inhibitors; Nefazadone as a phenylpiperazine anti-depressant unrelated to existing therapies.